Drug interactions
Dipyridamole + Regorafenib
Severity: Minor
Dipyridamole and Regorafenib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Regorafenib may inhibit the breast cancer resistance protein efflux transporter, which could raise systemic exposure to substrates of this transporter. Dipyridamole is not a well-characterised BCRP substrate, so any rise in its effect is theoretical and probably small.
What this interaction means in plain words
Dipyridamole and Regorafenib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Dipyridamole belongs to Cardiovascular; Regorafenib belongs to Oncology.
Why it happens
Possible inhibition of BCRP (ABCG2) efflux transport by regorafenib, reducing substrate clearance.
What to do
No empirical dose change is needed. Watch for hypotension, flushing or headache if dipyridamole effects appear exaggerated.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dipyridamole and Regorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Dipyridamole
- Dipyridamole + Riociguat Contraindicated
- Adenosine + Dipyridamole Major
- Betrixaban + Dipyridamole Major
- Dabigatran + Dipyridamole Major
- Dipyridamole + Regadenoson Major
- Dipyridamole + Venetoclax Major
Other interactions of Regorafenib
Frequently asked questions
Can I take Dipyridamole with Regorafenib?
MediHelp rates the interaction as minor. Dipyridamole and Regorafenib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Regorafenib may inhibit the breast cancer resistance protein efflux transporter, which could raise systemic exposure to substrates of this transporter. Dipyridamole is not a well-characterised BCRP substrate, so any rise in its effect is theoretical and probably small.
How serious is the interaction between Dipyridamole and Regorafenib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No empirical dose change is needed. Watch for hypotension, flushing or headache if dipyridamole effects appear exaggerated.
What other medicines interact with Dipyridamole?
MediHelp also lists interactions of Dipyridamole with, for example, Riociguat, Adenosine, Betrixaban. The full list is on the Dipyridamole page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
